Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ High Yield Corporate Bond ETF vs Sana Biotechnology Inc — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.69, while Sana Biotechnology Inc trades at $3.2 (market cap $873.84M). The key difference: iShares iBoxx $ High Yield Corporate Bond ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| HYG | SANA | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $81.32 | $5.92 |
52-Week Low | $78.72 | $2.68 |
Market Cap | — | $873.84M |
Enterprise Value | — | $848.03M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HYG trades at $79.68, up slightly by 0.04% today, but technical indicators signal a bearish trend with moving averages and overall signals pointing to selling pressure. The fund has declared dividends for 2026, including $0.37 and $0.41 payouts, amid a backdrop of high bond market volatility and investor caution. Recent news highlights elevated put volume and bearish bets against high-yield bonds, reflecting broader market uncertainty.
The outlook for HYG is cautious due to bearish technicals and macroeconomic headwinds like potential Fed rate hikes. Risks include interest rate sensitivity and inflation pressures, but the dividend yield may attract income-focused investors. Wall Street sentiment is mixed, with institutional flows into bond ETFs offering some support amid prevailing risks.
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
